IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapyJon M. Wigginton, Robert H. Wiltrout, Kristin L. Komschlies et al.|Journal of Clinical Investigation|2001Cited by 126
IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapyJon M. Wigginton, Robert H. Wiltrout, Eilene Gruys et al.|Journal of Clinical Investigation|2001Cited by 109